Clinical Perspectives and Future Directions in Newly Diagnosed Multiple Myeloma

Dr. Ajai Chari and NP Samantha Shenoy conclude the discussion by reflecting on the evolving management of newly diagnosed multiple myeloma (NDMM) and the clinical implications of recent advances in CD38-directed therapy. The faculty summarize how long-term follow-up from contemporary clinical trials has reinforced the importance of achieving deep responses while balancing efficacy, safety, and patient-centered treatment goals. The conversation explores the growing role of minimal residual disease (MRD) assessment, ongoing therapy, and individualized treatment duration as areas of continued clinical interest, while emphasizing that treatment decisions should remain tailored to each patient's overall health status and preferences. Dr. Chari and NP Shenoy also discuss practical considerations for multidisciplinary care, patient education, and longitudinal follow-up, highlighting the importance of shared decision-making as frontline treatment strategies continue to evolve and additional long-term evidence becomes available for patients with NDMM.